Temporary LTD Outage

The ARUP Laboratory Test Directory will be unavailable for approximately an hour beginning at 12:00am, Tuesday, January 23rd for required maintenance. 

Freeman-Sheldon Syndrome (MYH3) Sequencing Exon 17
Ordering Recommendation

Diagnostic testing for Freeman-Sheldon syndrome.

Polymerase Chain Reaction/Sequencing
7-14 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B). 
Specimen Preparation
Transport 3 mL whole blood. (Min: 1 mL) 
Storage/Transport Temperature
Unacceptable Conditions
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable 
Reference Interval
Interpretive Data
Background Information for Freeman-Sheldon Syndrome (MYH3) Sequencing Exon 17:
"Whistler appearance" due to facial muscle contractures, joint contractures of hands and feet, facial dysmorphism, strabismus, dental crowding, restricted cervical flexion, scoliosis, hearing loss, cryptorchidism and inguinal hernia.
Prevalence: Uncertain; approximately 100 cases have been reported to date.
Inheritance: Autosomal dominant.
Cause: Pathogenic MYH3 gene mutations.
Clinical Sensitivity: Approximately 70 percent.
Methodology: Bidirectional sequencing of MYH3 exon 17 which includes the two most common mutations, R672C and R672H.
Analytical Sensitivity and Specificity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Mutations outside exon 17 will not be detected.

Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Component Test Code*Component Chart NameLOINC
2002663FSS SEQ Specimen
2002664Freeman-Sheldon Syndrome Interpretation
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Whistling Face Syndrome